Damian Garde

Biography for Damian Garde

Damian Garde, Editor

Damian is an editor with Fierce's life sciences publications, writing for FierceBiotech, FierceMedicalDevices and FierceCRO. Prior to joining Fierce, he worked for Patch.com in Maryland, and The Albuquerque Journal and Weekly Alibi in Albuquerque, NM. Damian lives in Washington, DC, and considers himself the foremost Carmelo Anthony apologist in the greater metropolitan area. You can email him at dgarde@fiercemarkets.com and follow @DamianFierce on Twitter.

Articles by Damian Garde

French immuno-oncology biotech OSE eyes an EU IPO

The U.S. boom in biotech IPOs has largely failed to drift across the Atlantic and galvanize many floats in Europe, but France's OSE Pharma is looking to buck that trend in hopes of bankrolling late-stage studies for its immuno-oncology candidate.

Cubist makes Euro landfall with a $400M purse for antibiotics R&D

The antibiotics-focused Cubist Pharmaceuticals has opened up shop in Europe with a Swiss international headquarters, part of its plan to spend $400 million on infectious disease R&D this year and spotlight new treatments for global scourges.

Novo Nordisk wins EU approval for a diabetes combo with billion-dollar potential

Novo Nordisk picked up European approval for a combination of a long-acting insulin and its own Victoza, pioneering a once-a-day approach to Type 2 diabetes that could bring in blockbuster sales.

FDA advisers shoot down Clarus' pitch for a new low-T drug

Amid widespread safety concerns surrounding testosterone drugs, an FDA panel has recommended against Clarus Therapeutics' oral treatment, dimming the future for the company's sole product.

Biotech IPOs: ProQR soars and Foamix thuds amid a volatile market

For evidence of Wall Street's ongoing hesitance to embrace biotech startups, look no further than ProQR Therapeutics and Foamix Pharmaceuticals, two IPO debutantes with diametric fortunes on the market.

Merck's weekly diabetes drug stacks up to blockbuster Januvia in Phase III

Merck's new, once-a-week treatment for diabetes measured up to the company's top-selling Januvia in its first Phase III test, setting the stage for a Japanese regulatory application and stoking the drugmaker's hopes of another blockbuster in the space.

Flexion tanks as FDA clamps a hold on its lead osteoarthritis drug

Just months after pulling off a successful IPO, Flexion Therapeutics is left watching its shares plummet after the FDA forced it to halt a trial on its top prospect.

Tokai pockets $97M in IPO cash to get its cancer drug into Phase III

Cambridge, MA, biotech Tokai Pharmaceuticals pulled off a $97.2 million Wall Street debut, raising the money it needs to get its three-in-one treatment for prostate cancer into late-stage development.

Novo Nordisk takes the plunge on obesity, eyeing Seattle for a huge R&D bet

In the midst of its first major foray into treating obesity, Novo Nordisk is liking what it sees in the space, and now the Danish giant plans to hire hundreds of researchers in a gambit to develop new treatments for the global scourge.

Gilead's oncology contender comes up short in pancreatic cancer

Gilead Sciences' simtuzumab failed to meet its main goal in a Phase II pancreatic cancer trial, denting the potential of a therapy the company hopes can treat a wide range of malignancies.